Originally published In Press as doi:10.1074/jbc.M200331200 on February 20, 2002
J. Biol. Chem., Vol. 277, Issue 18, 15904-15912, May 3, 2002
Cubilin, a Binding Partner for Galectin-3 in the Murine
Utero-Placental Complex*
Sunday
Crider-Pirkle
,
Peggy
Billingsley
,
Charles
Faust
,
Daniel M.
Hardy
,
Vaughan
Lee
, and
Harry
Weitlauf
§¶
From the Departments of
Cell Biology and Biochemistry
and § Ob/Gyn, Texas Tech University Health Sciences Center,
Lubbock, Texas 79430
Received for publication, January 11, 2002, and in revised form, February 20, 2002
 |
ABSTRACT |
Galectin-3 is a lectin important in animal
development and regulatory processes and is found selectively localized
at the implantation site of the mouse embryo. To better understand the role of galectin-3 at the maternal-fetal interface, a binding partner
was isolated and characterized. Homogenates of uteroplacental tissue
were incubated with immobilized recombinant galectin-3, and
specifically bound proteins were eluted using lactose. The principal
protein, p400, had an Mr of 400,000 in
SDS-PAGE. Physical properties of p400 and amino acid sequences of seven
tryptic peptides were similar to cubilin from rats, humans, and dogs,
identifying p400 as the murine ortholog of cubilin. This was further
supported by the tissue distribution observed only in yolk sac, kidney, and ileum with monospecific antiserum for p400. Cubilin occurred in
yolk sac epithelium throughout pregnancy, but galectin-3 was there only
during the last week. Unexpectedly, cubilin was found only in
perforin-containing granules of uterine natural killer (uNK) cells,
although galectin-3 occurred throughout the cell cytoplasm. In
situ hybridization revealed cubilin mRNA in yolk sac
epithelium but not uNK cells, implying that yolk sac-derived cubilin is
endocytosed by uNK cells via galectin-3. This is consistent with
cubilin being an endogenous partner of galectin-3 at the maternal-fetal
interface and suggests an important role for cubilin in uNK cell function.
 |
INTRODUCTION |
Galectin-3 (gal-3)1 is
one of at least 10 members of a lectin family, which share a conserved
carbohydrate recognition domain and which exert their varied biological
effects through interaction with complementary
-galactoside ligands
of glycoprotein or glycolipid "counterreceptors." Since galectins
are divalent and are able to form multivalent aggregates, they can
cross-link counterreceptors, effecting cell-cell, cell-matrix, or
matrix-matrix interactions, thus possibly initiating signal
transduction. Isolation of several membrane or matrix counterreceptors
by affinity chromatography has revealed that galectins are linked to a
variety of important processes including neoplastic transformation,
cell adhesion, tumor invasiveness and metastasis, cellular
proliferation, and localized immunomodulation (see Ref. 1). gal-3 and
its mRNA are expressed in trophoblast cells of placenta as well as
in the granular uNK cells of the metrial gland and decidualized
endometrium of the murine implantation site (2-4). That finding, along
with the additional observation that gal-3 is absent from
nondecidualized endometrium between implantation sites and is not
present in uteri of nonpregnant females (3), strongly suggests that
this lectin has a pregnancy-related function at the maternal-fetal
interface. Although a role for gal-3 at the maternal-fetal interface is
not yet known, it may contribute in some fashion to cell adhesion, proliferation, or immunomodulation, all of which occur in other contexts. Therefore, to gain more insight into a role for this lectin
at the maternal-fetal interface, we isolated and characterized a
counterreceptor for gal-3 from tissues of the murine utero-placental complex that was identified as cubilin. This large protein is produced
by epithelial cells of the kidney, small intestine, and yolk sac, and
it can function as coreceptor for endocytosis of many important
biological molecules in these tissues. Consequently, given the
proximity of yolk sac to the maternal-fetal interface, the association
of cubilin with gal-3 is especially intriguing, as is its association
with the granules of uNK cells in the context of cell adhesion,
proliferation, or immunomodulation.
 |
EXPERIMENTAL PROCEDURES |
Animals--
Outbred Swiss-Webster mice were used for all
studies. Virgin females (10-12 weeks of age; Charles River,
Wilmington, MA) were selected at random stages of the estrous cycle,
paired with fertile males, and checked daily for the presence of a
vaginal plug (designated as day 1 of pregnancy).
Preparation of Lactosyl-Sepharose Affinity Matrix--
Sepharose
4B was suspended in an equal volume of 500 mM
Na2CO3, filtered in a Buchner funnel, and
washed with 5 volumes of 500 mM
Na2CO3. This was resuspended in an equal volume
of 500 mM Na2CO3; divinylsulfone
(10% of the gel volume) was added to activate the matrix; and the
slurry was stirred for 70 min gently at 20 °C, washed as above,
resuspended in an equal volume of 10% lactose in 500 mM
Na2CO3, and stirred for 15 h gently at
20 °C. The lactosyl-Sepharose matrix was washed as above, followed
by 5 volumes of distilled H2O and 5 volumes of PBS (pH
7.2). The gel was resuspended in an equal volume of PBS, packed in a
200-ml column (5 × 30 cm), and stored at 4 °C. All subsequent
procedures were done at 4 °C unless otherwise indicated.
Isolation of rgal-3--
Escherichia coli strain
JA221 was transformed with murine CBP35 cDNA in a pIN
IIIompA2 vector (gift of Dr. J. L. Wang (Michigan State
University)) (5) to produce rgal-3. A 10-ml culture, grown overnight in
Luria-Bertani broth, was used to inoculate 2 liters of Terrific Broth
(12 g/liter tryptone, 24 g/liter yeast extract, 2.31 g/liter
KH2PO4, 12.54 g/liter
K2HPO4, 4 ml/liter glycerol) containing 100 µg/ml ampicillin. This was allowed to grow with shaking at 37 °C
for 4 h, and then protein production was induced with the addition
of 50 mM
isopropyl-1-thio-
-D-galactopyranoside, and cells were
cultured with shaking at 20 °C for 16-24 h. Cells were harvested by
centrifugation (4000 × g, 20 min); washed in ice-cold
PBS; and lysed for 30 min on ice in lysis buffer (1 M Tris-HCl, pH 7.0, 10 mM 2-mercaptoethanol (2-ME), 30 units
of aprotinin, 10 µg/ml soybean trypsin inhibitor), 0.5 mg/ml
leupeptin, and 1 mM phenylmethylsulfonyl fluoride (PMSF).
The lysate was then centrifuged (10,000 × g, 30 min).
rgal-3 was purified from lysate supernatant using the
lactosyl-Sepharose affinity matrix. Immediately prior to use, the
column was washed with 10 volumes of PBS, and the lysate, containing rgal-3, was applied. Nonbinding material was removed with 5 volumes of
sucrose buffer (50 mM Tris-HCl, pH 7.6, 2 mM
2-ME, 300 mM sucrose), followed by 5 volumes of sucrose
buffer without 2-ME. rgal-3 was eluted with lactose elution buffer (300 mM lactose, a disaccharide specific for the carbohydrate
recognition domain of gal-3, 50 mM Tris-HCl, pH 7.6, 100 mM iodoacetamide). rgal-3 fractions were pooled, dialyzed
(1:40) versus four changes of PBS to remove lactose, and
concentrated by ultrafiltration using an Amicon stirred cell (PM-10
membrane; Amicon, Beverly, MA). Protein amounts were determined by
Bradford assay (Bio-Rad Protein Assay).
Preparation of rgal-3 Affinity Matrix--
The affinity
resin was prepared by hydrating cyanogen bromide-Sepharose with 0.001 N HCl (15 min), washed with coupling buffer (100 mM NaHCO3, pH 8.3, 500 mM NaCl),
and centrifuged (750 × g for 10 min). Supernatant was
discarded, and rgal-3 was added to the activated Sepharose at 8.4 mg to
1 g of gel and mixed for 6 h at 20 °C. After 10 min of
centrifugation at 750 × g, the pellet was mixed
overnight in coupling buffer with 200 mM glycine to block
any reactive sites remaining. The slurry was placed in a 1-ml column
and washed with coupling buffer, followed by 100 mM sodium
acetate, pH 4.0, 500 mM NaCl, and coupling buffer. It was equilibrated with 5 volumes of TET buffer (50 mM Tris-HCl,
pH 7.8, 1 mM EDTA, 1% Triton X-100) for isolation of
gal-3-binding proteins.
Preparation of Placental-Fetal Membrane Homogenate--
Animals
were killed by CO2 asphyxiation followed by cervical
dislocation at various times of pregnancy, and uteri were removed and
opened along the antimesometrial margin. Placentas and associated fetal
membranes were separated from uterine implantation sites, and fetuses
were discarded; maternal and fetal components were frozen separately in
liquid nitrogen and stored at
80 °C. Tissues were homogenized (PT
10/35; Brinkman, Westbury, NY) at 1.0 g of tissue/2 ml of buffer A
(PBS with 4.0 mM 2-ME, 1 mM PMSF) with Complete
Mini Protease Inhibitor Mixture (Roche Molecular Biochemicals) at 1 tablet/10 ml of solution with 1 mM EDTA and 300 mM lactose. The homogenate was centrifuged (10,000 × g for 20 min at 4 °C), and the supernatant was discarded.
The resulting pellet was homogenized with the equivalent of 1.5 g
of tissue/1 ml of buffer B (20 mM Na2PO4, pH 7.2, 1.0 M NaCl, 1 mM PMSF, and Complete Mini Protease Inhibitor Mixture) and
centrifuged (10,000 × g, 20 min). This pellet was
homogenized in buffer C (50 mM Tris-HCl, pH 7.8, 1 mM PMSF, and Complete Mini Protease Inhibitor Mixture)
again at the equivalent of 1.5 g of tissue/1 ml of buffer, and
centrifuged (10,000 × g, 20 min). This pellet was
homogenized in buffer C with 1% Triton X-100 at the equivalent of
1.5 g of tissue/1 ml and centrifuged (10,000 × g,
for 20 min). Protein content of the final supernatant (i.e.
the detergent extract of placental-fetal membranes) was determined by
the BCA method (Pierce). In a tissue survey experiment, extracts were
similarly prepared from fetal membranes, placentas with and without
fetal membranes, decidualized and nondecidualized endometrium,
artificially induced deciduomata, kidney, ileum, smooth muscle (large
bowel), heart, lung, spleen, brain, and liver.
Isolation of gal-3-binding Proteins from Placental-Fetal
Membranes--
gal-3-binding proteins were isolated by affinity
chromatography on rgal-3-Sepharose and eluted with lactose. In initial
experiments, placental-fetal membrane proteins were
125I-labeled (IODO-BEADs; Pierce) and applied to an rgal-3
matrix. Nonbinding material was eluted by extensive washing with TET
buffer containing 300 mM sucrose, specifically bound
proteins were eluted using TET in 300 mM lactose, and
200-µl fractions were collected. gal-3-binding proteins were run on
SDS-PAGE (4-15%) under reducing conditions (Ready Gels; Bio-Rad) and
autoradiographed. Preparative amounts of p400 were isolated batchwise,
using a slurry of placental-fetal membrane and rgal-3/Sepharose (10 mg
of placental-fetal membrane protein/mg of rgal-3), mixed for 4 h,
placed in a chromatography column (0.7 × 10 cm) and washed with
100 column volumes of TET. The matrix was resuspended in an equal
volume of TET containing 300 mM lactose and rotated in a
12 × 75-mm Falcon tube overnight. The slurry was put in a
500-µl microcentrifuge tube with a pinhole in the bottom and
containing a glass wool plug, fitted in a 12 × 75-mm Falcon tube
and centrifuged for 1 min at 188 × g. The quality of
each filtrate was checked by SDS-PAGE on a 4-15% gel under reducing
conditions and visualized with Coomassie Blue stain. Typically, 50 µg
of gal-3-binding proteins were recovered from placental-fetal membrane
extracts per 50 placental units.
Production of Anti-p400--
gal-3-binding proteins (137 µg),
eluted from a rgal-3 column, were electrophoresed on a 5% acrylamide
gel in nonreducing conditions and stained with Coomassie Blue. The
Mr 400,000 band was excised, frozen, homogenized
in PBS, and emulsified in an equal volume of Freund's complete
adjuvant. Half of the emulsion was injected intradermally at multiple
sites in a rabbit, and the remainder was injected intramuscularly in
the quadriceps muscle. Test bleeds were done at 6, 7, and 11 weeks; a
booster (30 µg of homogenized p400, but without adjuvant
emulsification) was given intramuscularly at 8 weeks. The rabbit was
exsanguinated by cardiac puncture at 12 weeks, blood was allowed to
clot for 1 h at 20 °C, and the clot contracted overnight.
Antiserum was collected, frozen in aliquots, and stored at
80 °C.
Specificity was demonstrated by Western blotting of gal-3-binding
proteins (1 µg) and placental-fetal membrane proteins (20 µg).
Samples were run on 4-15% polyacrylamide gels (Ready gels) under
nonreducing conditions and transferred to nitrocellulose. Blots were
blocked in 3% nonfat dry milk in TBS (10 mM Tris-HCl, pH
7.5, 200 mM NaCl) for 1-2 h at 20 °C, followed by
incubation overnight in primary antiserum at 1:25,000 (i.e.
p400 antiserum, preimmune serum, or a nonrelevant antiserum (a rabbit
antiserum (6) to the zonadhesion holoprotein purified from pig
spermatozoa)). Blots were washed (4 × 5 min) in TBS, incubated in
secondary antibody (1:20,000 (ImmunoPure goat anti-rabbit IgG
horseradish peroxidase-conjugated; Pierce) in 3% milk in TBS for 30 min, washed in TBS, incubated for 5 min in substrate (Super Signal West
Pico chemiluminescence substrate; Pierce), and exposed to film. Some
blots were incubated in secondary antibody alone as a negative control.
For use in immunohistochemistry, anti-p400 was made monospecific by
absorption with acetone mouse liver powder (i.e. liver
absorbed anti-p400) to remove the Mr 70,000 immunoreactive species found in most tissues. 300 µl of anti-p400
(1:50 in TBST plus Complete Mini Protease Inhibitor Mixture) and 5 mg
of liver powder were mixed for 30 min and centrifuged at 20,000 × g for 15 min. Supernatant was then collected, and the
process was repeated twice. This treatment effectively removed anti-p70
from antiserum; aliquots of liver absorbed, monospecific anti-p400 were
stored at
20 °C.
Deglycosylation of p400--
The extent of glycosylation of p400
was examined with endoglycosidases using a protocol modified from
manufacturer's instructions (Glycofree Deglycosylation Kit; Prozyme,
San Leandro, CA). Briefly, 3 µg of gal-3-binding proteins isolated
from placental-fetal membrane were dialyzed against 250 mM
sodium phosphate buffer, pH 7.0, SDS was added to 0.1% final
concentration, and proteins were denatured at 65 °C for 5 min. The
sample was cooled to 20 °C; Triton X-100 was added to 0.75% final
concentration; 1 µl of peptide N-glycosidase F (500 units/ml), endo-O-glycosidase (1.25 units/ml), or sialidase A (5 units/ml) was added; and samples were incubated at 37 °C. Aliquots were removed at various times up to 72 h and subjected to
nonreducing SDS-PAGE (5%) and Western analysis with anti-p400.
Assay for Intermolecular and Intramolecular Disulfide
Bonds--
gal-3-binding proteins were trichloroacetic
acid-precipitated, washed with ice-cold 90% acetone, and dried. The
pellet was dissolved in 0.01 N NaOH, denatured at 65 °C
for 10 min in nonreducing Laemmli buffer, loaded onto a 4% acrylamide
tube gel, and electrophoresed at 100 V for 3 h. The tube gel was
extruded, incubated in reducing buffer (loading buffer plus 20 mM dithiothreitol for 15 min), and loaded onto a 4%
preparative slab gel run at 100 V for 1 h in a second dimension.
The gel was either silver-stained or transferred to nitrocellulose and
probed with anti-p400 for Western analysis.
Amino Acid Sequence Analysis of p400--
Amino acid sequencing
of p400 was performed by Prof. C. Slaughter (Howard Hughes Medical
Institute, University of Texas Medical School, Dallas, TX). Peptides,
separated by reverse phase high pressure liquid chromatography on a
150-mm RP300 column (PerkinElmer Life Sciences), were subjected to
automated Edman degradation using a model 477A amino acid sequencer
(Applied Biosystems, Foster City, CA). Sequences of p400 peptides were
compared for alignment with proteins of the National Center
Biotechnology Information data bank.
Tissue Collection for Immunohistochemistry and in Situ
Hybridization--
Tissue was prepared from uterine horns of various
days of pregnancy, fixed in 4% paraformaldehyde in PBS overnight, and
embedded (Paraplast Plus, Sherwood Medical Laboratories, St. Louis,
MO), and 5-µm serial sections were mounted on Superfrost Plus slides (Fisher). In some experiments, a ligature was made at one or both utero-tubal junctions on day 1 of pregnancy to create a unilateral or
bilateral sterile pseudopregnant horn (3), using a standardized stimulus (i.e. an 11-mm cut along the antimesometrial margin
of the ovarian end of the uterine horn) delivered on day 4; the
resulting deciduomata were harvested on days 8-14 and processed as for
normal implantation sites.
Immunostaining--
Tissue sections were deparaffinized in
xylene, rehydrated in a gradient series of ethanol, treated in 0.3%
hydrogen peroxide/methanol (20 min), washed in PBS plus 0.1% bovine
serum albumin (fraction V; Fisher), and placed 10 min in boiling 10 mM citrate buffer, pH 6. Slides were cooled, washed 30 min,
and blocked in 1% bovine serum albumin plus 1% normal goat serum in
PBS); this was followed by incubation with primary antibody (3 h
at 20 °C.). Anti-p400 and preimmune rabbit sera (negative control)
were used at 1:24,000. Sections were incubated in goat anti-rabbit IgG
biotinylated secondary antibody (30 min at 20 °C; Vectastain
Elite ABC kit, Vector, Burlingame, CA), washed with PBS, and covered
with the ABC reagent (30 min at 20 °C). Slides were washed in PBS,
developed in 100 mM Tris-HCl, pH 7.2, with
3,3'-diaminobenzidine and H2O2, counterstained
with Mayer's hematoxylin, dehydrated, and coverslipped. Anti-perforin (rat IgG2a anti-mouse; Alexis, San Diego, CA) or the isotypic control
(rat IgG2a anti-lyt (53-6.72)) was used at 1:400; anti-gal-3 (rat IgG2a
anti-Mac-2 (M3/38)) or the isotypic control (anti-lyt) was prepared and
used at 1:1600 (3). Slides were washed in PBS and incubated in goat
anti-rat horseradish peroxidase secondary antibody (Cappel,
Durham, NC) for 90 min, washed, and
3,3'-diaminobenzidine-developed as for the anti-p400.
Dual Label Fluorescence Immunochemistry--
Slides were treated
as above, through the primary antibody incubation step (anti-p400
1:4,000, anti-perforin 1:400, or anti-gal-3 1:800), washed in PBS, and
incubated with secondary antibodies (Alexa Fluor 488 goat anti-rat IgG
and Alexa Fluor 594 goat anti-rabbit IgG; Molecular Probes, Inc.,
Eugene, OR) for 45 min at 37 °C. Slides were washed in PBS three
times and then in PBS at pH 8.5 mounted in MOWIOL (Calbiochem)
solution under glass coverslips and viewed with a Zeiss Axiovert
microscope using standard epifluorescence.
In Situ Hybridization--
Mouse cubilin (GenBankTM
accession number AF 197159) PCR primers were used to prepare a 394-bp
cDNA with T7 promoter (see Table I, p. 12004, in Ref. 7) and
verified by DNA sequencing. A 940-bp gal-3 cDNA (8) clone, pMac2.3,
was made (4). Sense and antisense cRNA probes were labeled with
[
-35S]UTP (>1000 Ci/mmol; PerkinElmer Life Sciences),
separated from unincorporated label on Biogel-P30 spin columns
(Bio-Rad), and used for in situ hybridization (4). Sections
were deparaffinized, rehydrated, and treated with proteinase K and with
acetic anhydride. Slides were prehybridized for 4 h at 20 °C;
hybridized >16 h at 50 °C with probes (1 × 106
cpm sense or antisense/slide); treated with RNase A; washed in 15 mM NaCl, 1.5 mM sodium citrate for 2 h at
65 °C; and dehydrated in ethanol with 300 mM ammonium
acetate. Slides were dried and exposed 3 days on film, and
hybridization signal intensity was estimated. Slides were dipped in
NTB-2 emulsion (Eastman Kodak Co.), exposed 7-14 days at 4 °C,
developed in Kodak D19 developer, counterstained with Mayer's
hematoxylin, and viewed on an Olympus BX50 microscope (Leeds
Instruments Inc., Irving, TX) by light and dark field optics.
 |
RESULTS |
Isolation of gal-3-binding Proteins--
Since gal-3 may have an
important physiological role at the maternal-fetal interface,
gal-3-binding proteins were isolated from placental-fetal membrane
extracts using immobilized rgal-3. Labeled, nonbinding protein
(~99%) passed through the column (Fig. 1), and no more was released by a sucrose
wash. In contrast, a sharp peak of radioactivity (~1%) eluted with
lactose. After lactose removal, virtually all rebound to the rgal-3
column and could be re-eluted with lactose but not sucrose, confirming
specific binding.2
gal-3-binding proteins were run on SDS-PAGE under reducing conditions and visualized autoradiographically. The major labeled gal-3-binding protein is larger than 200 kDa, extrapolating to about 400 kDa (p400)
with several minor bands2 around 120 kDa. Larger amounts of
gal-3-binding proteins isolated by a batch method were detected with
Coomassie Blue after SDS-PAGE (Fig. 2);
again, the major protein is about Mr 400,000, with much fainter ones around Mr 120,000. p400
was selected for further study, because as the major gal-3-binding
protein, it may be important for gal-3 function in the implantation
complex.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
Elution profile of 125I-labeled
placental-fetal membrane proteins from mouse uteroplacental
complex. Labeled placental-fetal membrane proteins from mouse
uteroplacental complex were passed through a gal-3 affinity column. The
unbound, flow-through is shown in the inset, and the portion
specifically eluted with lactose, containing the gal-3-binding
proteins, is shown after the arrow.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
SDS-PAGE of gal-3-binding proteins under
reducing conditions. Proteins were stained with Coomassie Blue;
lane 1 contains the markers, and lane
2 contains the gal-3-binding proteins.
|
|
Specificity of Anti-p400--
A batch method provided sufficient
p400 to produce an antiserum for studies of its chemical and
immunohistochemical properties. The specificity of anti-p400 was
examined as follows: gal-3-binding proteins and placental-fetal
membrane extracts were subjected to PAGE, blotted to nitrocellulose,
and probed with anti-p400 (Fig. 3); an
immunoreactive band (lane 1) extrapolating to
about Mr 400,000 is found, with a slower moving
band extrapolating to about Mr 800,000. Immunoreactive proteins in placental-fetal membranes are found
(lane 2) at an Mr of
400,000 and an Mr of 70,000. These did not react
with preimmune serum (lanes 3 and 4),
a nonrelevant antiserum, or secondary antibody alone. After liver
powder adsorption, the antiserum was monospecific2 for
p400.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 3.
Western blot analysis of gal-3-binding
proteins and placental-fetal membrane proteins. Lanes
1 (gal-3-binding proteins) and 2 (placental-fetal
membrane) show results of probing with anti-p400 antiserum, and
lanes 3 and 4 show results of probing
these same fractions with preimmune serum. Molecular weight markers are
indicated; PAGE was done under nonreducing conditions.
|
|
Chemical Characteristics of p400--
Electrophoretic mobility of
p400 was run under nonreducing and reducing conditions to see if it
contains intermolecular or intramolecular disulfide bonds.
One-dimensional analysis, visualized with silver staining (Fig.
4A), shows reduced p400 runs
slower than the nonreduced form; Western blot analysis (Fig.
4C) confirms both are p400. This is supported by
two-dimensional gel analyses (Fig. 4, B and D),
in which the p400 is above a theoretical diagonal on the gel, showing
that migration was slower under nonreducing conditions. These results
are only compatible with the presence of intramolecular disulfide bonds
in a p400 molecule, so p400 is a monomer whose tertiary structure is
stabilized by disulfide bonds. Finally, anti-p400 always reacted much
more intensely with nonreduced p400 than an equal amount of reduced
protein. Since nonreduced p400 was used as immunogen to make this
antiserum, loss in Western sensitivity to p400 after reduction probably
corresponds to epitope loss from p400.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Analyses of p400 under nonreducing and
reducing conditions. A and B, silver stain
analyses. C and D, Western blot analyses using
the monospecific anti-p400 antiserum. A and C
show the results of one-dimensional SDS gel analyses, whereas
B and D show the results of two-dimensional SDS
gel analyses.
|
|
The p400 was exposed to glycosidases and subjected to Western
analysis to determine whether it is glycosylated. After 18 h of
incubation (Fig. 5), the electrophoretic
mobility of p400 increased about 10% (lane 6)
compared with untreated (lanes 1 and
8) and mock-treated samples (lane 7).
Thus, p400 is a glycoprotein with significant amounts of
N-linked carbohydrate. Incubations of 48 and 72 h or
treatment with O-glycosidases or sialidases, produced no
additional detectable changes.2

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 5.
Time course for N-linked deglycosylation of
p400. Lanes 1 and 8, untreated
zero time; lane 2, 7 min; lane
3, 15 min; lane 4, 30 min;
lane 5, 1 h; lane 6,
18 h; lane 7, mock-treated for 18 h.
|
|
Amino acid sequences of seven peptides of p400 (p400-1 through p400-7)
are shown in Fig. 6A. The p400
peptides bear a close resemblance to segments of a full-length protein
of rat (AAC 71661), human (AAC 82612), and dog (AAF 14258);
i.e. of the 73 amino acids from p400, 72.6% are identical
versus those in rat, 69.9% versus those in
human, and 67% versus those in dog. 12 of the remaining 21 nonidentical p400 rat-cubilin amino acid pairs are conservative substitutions. In addition, for the only overlap with the recently published fragment of mouse cubilin (AAF 61487), all nine amino acids
of p400-7 are identical. Alignment of these seven peptide fragments
with rat cubilin is also shown to map them relative to the full-length
rat sequence (Fig. 6B). Because these highly similar
peptides are dispersed across the rat sequence, we conclude that p400
is indeed most likely cubilin.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6.
p400 is the mouse ortholog of cubilin.
A, sequence comparison of p400 peptides versus
cubilin of other species. B, map of mouse cubilin peptides
aligned against the 3623 amino acid sequence of rat cubilin, predicted
from its cDNA (12).
|
|
Tissue Distribution of p400--
Based on known tissue
distributions of cubilin, a survey for p400 was done in further support
of this conclusion. Western blot analyses of tissues from pregnant
females were done with unadsorbed anti-p400 to survey p400 distribution
(Fig. 7). Immunoreactive p400 is seen at
Mr 400,000 in 10 µg of protein isolated from
fetal membranes (i.e. yolk sac (lane
1) and placental-fetal membranes (lane
2) but not placenta alone (lane 3)).
Similarly, p400 was in kidney (lane 7) and small
intestine (lane 14). No p400 was observed in
normal implantation sites (decidua; lane 4), in
artificially stimulated decidualized endometrium (deciduoma;
lane 5), or in nondecidualized endometrium from
virgin uteri (lane 6). Heart (lane
8), liver (lane 9), spleen
(lane 10), brain (lane 11),
lung (lane 12), and smooth muscle
(i.e. large intestine; lane 13) were also negative; increasing the total protein of all tissues to 30 µg
again yielded negative results.2 Immunoreactive material
was observed (Fig. 7) at Mr 70,000 in liver
(lane 9), placenta (lane
3), fetal membranes (lane 1), and placental-fetal membrane (lane 2); increasing
total protein to 30 µg revealed p70 in all tissues except
kidney.2 In conclusion, p400 is only in yolk sac, kidney,
and small intestine, confirming that it is murine cubilin.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 7.
Tissue survey for p400 using western blot
analysis. Lane 1, isolated yolk sac (fetal
membranes); lane 2, placental-fetal membranes;
lane 3, isolated placenta; lane
4, decidualized endometrium from a normal implantation site
(decidua); lane 5, decidualized endometrium from
an artificially induced deciduoma; lane 6,
nondecidualized endometrium from a virgin uterus; lane
7, kidney; lane 8, heart;
lane 9, liver; lane 10,
spleen; lane 11, brain; lane
12, lung; lane 13, large intestine;
lane 14, small intestine (all 10 µg of total
protein per lane).
|
|
Spatiotemporal Pattern of Expression of p400--
The pattern of
its expression in implantation sites was determined by probing
histologic sections with liver-absorbed anti-p400. Immunoreactive
protein was detected in yolk sac endoderm as early as day 6, and it was
present at the apical surface of those cells throughout the remainder
of pregnancy, as shown specifically for day 15 (Fig.
8, A1 and A4); it
was also clear that no immunoreactive material occurs in the placenta
per se. In situ hybridization studies with antisense cubilin
cRNA revealed, as shown for day 15 (Fig. 8, A2,
A3, A5, and A6), that the gene is
transcribed in yolk sac endoderm during the entire course of pregnancy.
Unexpectedly, anti-p400 reacted with the cytoplasmic granules of the
large granular cells from day 10 through day 21, as shown for day 16 (Fig. 9, B1 and
C1). These are characterized as uNK cells, because they also
label with anti-perforin (Fig. 9, B2) (9-11). Indeed, dual labeling with anti-p400 and anti-perforin demonstrates that both proteins are localized to the same granules (Fig. 9, B3).
Although perforin-positive uNK cells are detected in decidua as early
as day 5, p400 is not detected in these cells until day 10 and
thereafter. Furthermore, no cubilin mRNA was detectable in uNK
cells at any time, as shown for day 14 (Fig.
10).

View larger version (136K):
[in this window]
[in a new window]
|
Fig. 8.
Localization of cubilin and gal-3 proteins
and their mRNA in yolk sac cells from day 15 implantation
sites. Adjacent sections are used for cubilin protein and mRNA
(A1-A3), cubilin controls (A4-A6), gal-3 protein
and mRNA (B1-B3); and gal-3 controls
(B4-B6). A1, probed with anti-cubilin
(arrow); A4, probed with preimmune serum as
negative control; A2 and A3, probed with
antisense [35S]cubilin riboprobes and detected by
autoradiography (light field and dark field, respectively);
A5 and A6, probed with sense
[35S]cubilin riboprobes as negative controls (light field
and dark field, respectively). B1, probed with monoclonal
anti-gal-3 (arrow); B4, probed with nonrelevant
monoclonal antibody 53-6.72 as a negative isotypic control;
B2 and B3 (arrows), probed with
antisense [35S]gal-3 riboprobes and detected by
autoradiography (light field and dark field, respectively);
B5 and B6, probed with sense
[35S]gal-3 riboprobes as negative controls (light field
and dark field, respectively). Note the abundant localization of
cubilin mRNA (A2 and A3, arrows)
and gal-3 mRNA (B2 and B3, arrows)
in yolk sac cells. Bar (A1), 80 µm (applies to
all panels).
|
|

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 9.
Dual localization of cubilin, perforin, and
gal-3 protein in day 16 implantation sites. A1-A7,
yolk sac; B1-B7 and C1-C7, metrial gland cells.
A1, B1, and C1, cubilin; A2
and C2, gal-3; B2, perforin; A3 and
C3, overlay of cubilin and gal-3 expression; B3,
overlay of cubilin and perforin expression. A4-A7, controls for cubilin and
gal-3 in yolk sac; A4, rabbit preimune serum as cubilin
negative control in the presence of anti-gal-3 (A5).
A6, anti-cubilin in the presence of the nonrelevant
monoclonal antibody 53-6.72 as gal-3 negative control (A7).
B4-B7, controls for cubilin and perforin in metrial gland
cells; B4, rabbit preimmune serum as cubilin negative
control in the presence of anti-perforin (B5).
B6, anti-cubilin in the presence of nonrelevant monoclonal
antibody 53-6.72 as perforin negative control (B7).
C4-C7, controls for cubilin and gal-3 in metrial gland
cells; C4, rabbit preimmune serum as cubilin negative
control in the presence of anti-gal-3 (C5). C6,
anti-cubilin in the presence of nonrelevant monoclonal antibody
53-6.72 as gal-3 negative control (C7). Bar
(A1), 20 µm (applies to all panels).
|
|

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 10.
Localization of cubilin protein and mRNA
in metrial gland cells from day 14 implantation sites.
A-C, cubilin protein and mRNA; D-F, cubilin
controls. A, section probed with anti-cubilin; D,
adjacent section probed with preimmune rabbit serum as negative
control; B and C, adjacent section probed with
antisense [35S]cubilin riboprobes and detected by
autoradiography (light field and dark field, respectively);
E and F, adjacent section probed with sense
[35S]cubilin riboprobes as negative controls.
bv, blood vessel. Bar (A), 40 µm
(applies to all panels).
|
|
Comparison of Spatiotemporal Patterns of Expression of gal-3
and Cubilin--
The cellular sites of synthesis of these proteins and
their mRNAs were examined on adjacent histologic sections, using
both monoclonal antibody against gal-3 and radiolabeled gal-3 antisense cRNA as probes. On day 5 of pregnancy, decidualizing endometrium and
uNK cells were labeled with both the antibody and the cRNA, and by day
12 trophoblast as well as decidual and uNK cells were observed to be
expressing both the gal-3 mRNA and protein, as previously reported
(4). However, while there was no evidence of labeling of the visceral
yolk sac epithelium with either the gal-3 antibody or cRNA up to day 12 of pregnancy, patchy labeling was observed with both probes on day 12. Throughout the remainder of pregnancy, an increasing proportion of
epithelial cells of the visceral yolk sac were labeled with both gal-3
antibody and cRNA probes, as shown for day 15 (Fig. 8, B1
and B3).
Results of probing sections of day 16 yolk sac simultaneously with
anti-p400 and anti-gal-3 are shown in Fig. 9, A1-A3. The p400 was observed mainly in the apical portion of the cells (Fig. 9,
A1), while gal-3 appeared to be distributed throughout the cytoplasm (Fig. 9, A2); superimposition of these images
suggests an overlap of these proteins within the apical cytoplasm (Fig. 9, A3). Although anti-gal-3 labels uNK cells (Fig. 9,
C2), it is localized mainly in the cytoplasm and possibly
the plasma membrane; it does not appear to be directly associated with
p400 within perforin-positive granules (Fig. 9, C1-C3).
Finally, to determine if p400 is also present in uNK cells associated
with artificially stimulated deciduomata, which do not have an adjacent
yolk sac, deciduomata sections were probed with anti-perforin and
anti-p400. Granules were labeled with anti-perforin as well as
anti-p400. In situ hybridization work on adjacent sections demonstrated that the cells did not contain cubilin
mRNA.2
 |
DISCUSSION |
This study demonstrates that a monomeric protein, p400, ~400
kDa, can be isolated from homogenates of murine uteroplacental complex
by affinity chromatography with immobilized rgal-3. Peptide fragments
of p400 have amino acid sequences similar to those in cubilin of other
species. Although the complete amino acid sequence of murine cubilin is
unknown, its sequence has been deduced from full-length cDNA clones
of several other species (rat, AAC 71661; human, AAC 82612; and dog,
AAF 14258). Also, p400 is similar in size to cubilin, which is a
460-kDa peripheral membrane protein with 13% of its mass accounted for
by carbohydrate. Like cubilin, p400 is heavily glycosylated and has
intramolecular disulfide bonds. Finally, p400 is found only in the yolk
sac, kidney, and small intestine, and thus its tissue distribution is
identical to that of cubilin (12). Consequently, we conclude that p400 is the mouse ortholog of cubilin.
Cubilin has eight N-terminal epidermal growth factor-like domains
followed by 27 "CUB" domains (12), characterized as conserved stretches of amino acids separated by nonconserved regions of variable
length. CUB domains are predicted to result from a barrel-like structure with two layers of five-stranded
-sheets, stabilized by
two disulfides from four conserved cysteines, and with
-turns in a
surface-exposed position, similar to antigen binding regions of IgG
(13). CUB domains 5-8 are the binding site for intrinsic factor-vitamin B12 complex, and domains 13 and 14 bind the
"receptor-associated protein," a chaperone-like protein that
protects multiple ligand binding sites of processed low density
lipoprotein receptor family proteins (15, 16). Other proteins known to
bind cubilin with high affinity include megalin, a 600-kDa intrinsic
membrane protein, which functions as a multiligand receptor and is
localized in clatherin-coated pits of absorptive epithelium in kidney
and yolk sac (12, 16-19); IgG
light chain (20); holoparticle high density lipoprotein (21); transferrin (22); and apolipoprotein A-I
(23). That cubilin comprises several "specific" binding sites for
these and presumably other molecules accounts for its capacity as a
multiligand receptor or carrier and explains its ability, possibly in
association with megalin, to facilitate endocytosis of a variety of
proteins (7, 12, 14).
With the identification of p400 as cubilin, it was expected that
anti-p400 would label yolk sac epithelium (16-18). Consistent with
observations on the ontogeny of cubilin in rats (17), our in
situ hybridization studies in mice show that the gene is
transcribed in extraembryonic endoderm of visceral yolk sac as early as
day 6 of pregnancy through term. The importance of cubilin in the yolk
sac has become clear with a demonstration that it was the antigenic
target of "teratogenic antibodies" in previous studies (16,
24-26). In this earlier work, it was found that antibodies raised
against yolk sac or kidney and administered to pregnant rats (27) or
anti-p400 against mouse cubilin administered to pregnant
mice2 during the period of organogenesis resulted in severe
fetal abnormalities and death. Although the mechanism responsible for
the pathological effect of the antibodies is unknown, they localized in
yolk sac epithelium, possibly inhibiting the endocytic apparatus in
those cells (25-27). Since rodent yolk sac is the major portal for
maternal-fetal exchange prior to development of chorioallantoic
circulation (28), it is presumed that disruption of transport of
nutrients, such as maternal serum proteins, vitamin B12,
and cholesterol-containing lipoproteins, during the critical phase of
organogenesis could be involved (12, 25, 29).
Having isolated cubilin as a gal-3 binding partner and having
demonstrated its expression in yolk sac epithelium, it became important
to determine whether there was overlap in the tissue distributions of
these two molecules and thus the potential for them to interact
in vivo. Probing sections of the implantation site with
anti-gal-3 and with antisense gal-3 cRNA confirmed earlier observations
of its expression in trophoblast cells, decidualized endometrial cells,
and uNK cells throughout the course of pregnancy (4). Although neither
the gal-3 protein nor its mRNA were detected in yolk sac epithelium
before day 12, both were present in increasing amounts throughout the
last week of pregnancy, and thus it is possible that during that time
cubilin and gal-3 do interact in this region. The prospect of a
mechanism by which gal-3 might alter the cubilin-dependent
uptake of specific ligands by yolk sac during the last week of
pregnancy is potentially very important. However, that interesting
question remains to be answered by future experiments.
The observation that cubilin accumulates in perforin-positive granules
of the uNK cells was completely unexpected. These cells, considered to
be a subset of NK lymphocytes, accumulate in large numbers in the
decidua basalis and the metrial gland of the rodent implantation site
(30, 31). Their cytoplasmic granules contain perforin and granzyme,
typical of cytolytic lymphocytes (32). However, compared with
peripheral NK cells, uNK cells are notoriously poor killers of YAC cell
targets in vitro, especially after recovery from the uterus
in the latter half of pregnancy (33). While the uNK cells are more
potent when stimulated with interleukin-2 (34), normally they do not
mount a damaging immune reaction against the semiallogeneic products of
conception. Although the importance of uNK cells to pregnancy seems to
be that they influence developing placental vasculature by production
of proteases, matrix, or biologically active factors (30, 35, 36), the
question of why they do not mount an effective immune response against placenta or extraembryonic membranes may be just as important to our
ultimate understanding of the biology of the implantation site.
Since the lytic granules of NK cells are dual function organelles,
which combine the function of secretory and prelysosomal compartments
(37), the finding of immunoreactive cubilin in the cytoplasmic granules
of uNK cells raises several interesting questions. First, what is the
source of cubilin in uNK cells? Since its mRNA was not detected in
these cells, the gene appears not to be transcribed. Although adjacent
yolk sac is a likely source, the observation that it is present in uNK
cells in artificially induced deciduomata, which are not associated
with the developing yolk sac, is compatible with cubilin also being
taken up from the systemic circulation. Additionally important and
interesting questions include the following. What is the mechanism of
cubilin uptake by the uNK cells? Once cubilin is in uNK cells, what is its vectoring pathway to the granules? What is the final molecular form
of immunoreactive cubilin in the granules? What is the nature of its
association with perforin or granzyme in the granules? What is the
function of cubilin in uNK granules? Finally, what are the details of
the relationship of gal-3 to cubilin within uNK cells; i.e.
does gal-3 facilitate a cubilin function or vice versa? Cubilin uptake
by uNK cells might be of major significance if it reflects some
mechanism for sampling or processing fetal antigens or for altering
immune function by modifying the ability of granules to lyse potential targets.
The original objective of this work, to isolate a binding partner for
gal-3 in the uteroplacental complex as a step toward elucidating the
role of that lectin in pregnancy, was achieved with the identification
of cubilin. The finding that it co-localized with the lectin in yolk
sac epithelium in the last week of pregnancy is intriguing and may
suggest the existence of unappreciated mechanisms governing
maternal-fetal exchanges. The additional finding that cubilin
accumulates in uNK cells may also have far reaching implications for
the localized modulation of the immune system that occurs at the
implantation site. These observations provide important new directions
for research of the maternal-fetal interface.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants HD-29801 (to H. M. W.), HD-35166 (to D. M. H.), and HD-07271 (to S. C.-P.), the South Plains Foundation, the Houston Endowment, and
the Texas Tech University Health Sciences Center Laboratory for the
Study of Reproduction.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of Cell
Biology and Biochemistry, Texas Tech University Health Sciences Center,
3601 4th St., Lubbock, TX 79430. Fax: 806-743-2990; E-mail: harry.weitlauf@ttuhsc.edu.
Published, JBC Papers in Press, February 20, 2002, DOI 10.1074/jbc.M200331200
2
S. Crider-Pirkle, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
gal-3, galectin-3;
rgal-3, recombinant gal-3;
PBS, phosphate-buffered saline;
2-ME, 2-mercaptoethanol;
PMSF, phenylmethylsulfonyl fluoride;
uNK cells, uterine natural killer cells.
 |
REFERENCES |
| 1.
|
Perillo, N. L.,
Marcus, M. E.,
and Baum, L. G.
(1998)
J. Mol. Med.
76,
402-412[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Knisley, K. A.,
and Weitlauf, H. M.
(1993)
J. Reprod. Fertil.
97,
521-527[Abstract/Free Full Text]
|
| 3.
|
Phillips, B.,
Knisley, K.,
Weitlauf, K. D.,
Dorsett, J.,
Lee, V.,
and Weitlauf, H. M.
(1996)
Biol. Reprod.
55,
548-558[Abstract]
|
| 4.
|
Lee, V. H.,
Lee, A. B.,
Phillips, E. B.,
Roberts, J. K.,
and Weitlauf, H. M.
(1998)
Biol. Reprod.
58,
1277-1282[Abstract/Free Full Text]
|
| 5.
|
Agrwal, N.,
Sun, Q.,
Wang, S-Y.,
and Wang, J. L.
(1993)
J. Biol. Chem.
268,
14932-14939[Abstract/Free Full Text]
|
| 6.
|
Hickox, J. R., Bi, M.,
and Hardy, D. M.
(2001)
J. Biol. Chem.
276,
41502-41509[Abstract/Free Full Text]
|
| 7.
|
Hamad, S. M.,
Barth, J. L.,
Knaak, C.,
and Argraves, W. S.
(2000)
J. Biol. Chem.
275,
12003-12008[Abstract/Free Full Text]
|
| 8.
|
Cherayil, B. J.,
Weiner, S. J.,
and Pillai, S.
(1989)
J. Exp. Med.
170,
1959-1972[Abstract/Free Full Text]
|
| 9.
|
Parr, E. L.,
Parr, M. B.,
and Young, J. D-E.
(1987)
Biol. Reprod.
37,
1327-1335[Abstract]
|
| 10.
|
Kawasaki, A.,
Shinkai, Y.,
Kuwana, Y.,
Furuya, A.,
Ligo, Y.,
Hanai, N.,
Itoh, S.,
Yagita, H.,
and Okumura, K.
(1990)
Int. Immunol.
2,
677-684[Abstract/Free Full Text]
|
| 11.
|
Kusakabe, K.,
Okada, T.,
Sasaki, F.,
and Kiso, Y.
(1999a)
J. Vet. Med. Sci.
61,
1093-1100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Moestrup, S. K.,
Kozyraki, R.,
Kristiansen, M.,
Kaysen, J. H.,
Rasmussen, H. H.,
Brault, D.,
Pontillon, F.,
Goda, F. O.,
Christensen, E. I.,
Hammond, T. G.,
and Verroust, P. J.
(1998)
J. Biol. Chem.
273,
5235-5242[Abstract/Free Full Text]
|
| 13.
|
Bork, P.,
and Beckmann, G.
(1993)
J. Mol. Biol.
231,
539-545[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Birn, H.,
Verroust, P. J.,
Nexo, E.,
Hager, H.,
Jacobsen, C.,
Christensen, E. I.,
and Moestrup, S. K.
(1997)
J. Biol. Chem.
272,
26497-26504[Abstract/Free Full Text]
|
| 15.
|
Kristiansen, M.,
Kozyraki, R.,
Jacobsen, C.,
Nexo, E.,
Verroust, P. J.,
and Moestrup, S. K.
(1999)
J. Biol. Chem.
274,
20540-20544[Abstract/Free Full Text]
|
| 16.
|
Sahali, D.,
Mulliez, N.,
Chatelet, F.,
Dupuis, R.,
Ronco, P.,
and Verroust, P.
(1988)
J. Exp. Med.
167,
213-218[Abstract/Free Full Text]
|
| 17.
|
Sahali, D.,
Mulliez, N.,
Chatelet, F.,
Laurent-Winter, C.,
Citadelle, D.,
Sabourin, J-C.,
Roux, C.,
Ronco, P.,
and Verroust, P.
(1993)
Am. J. Pathol.
142,
1654-1667[Abstract]
|
| 18.
|
Le Panse, S.,
Ayani, E.,
Nielsen, S.,
Ronco, P.,
Verroust, P.,
and Christensen, E. I.
(1997)
Eur. J. Cell Biol.
72,
257-276[Medline]
[Order article via Infotrieve]
|
| 19.
|
Le Panse, S.,
Verroust, P.,
and Christensen, E. I.
(1997)
Exp. Nephrol.
5,
375-383[Medline]
[Order article via Infotrieve]
|
| 20.
|
Bautman, V.,
Verroust, P. J.,
Navar, G. L.,
Kaysen, J. H.,
Goda, F. O.,
Campbell, W. C.,
Simon, E.,
Pontillon, F.,
Lyles, M.,
Bruno, J.,
and Hammond, T. G.
(1998)
Am. J. Physiol.
275,
F246-F254[Abstract/Free Full Text]
|
| 21.
|
Hammad, S. M.,
Stefansson, S.,
Twal, W. O.,
Drake, C. J.,
Fleming, P.,
Remaley, A.,
Brewer, H. B., Jr.,
and Argraves, W. S.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
10158-10163[Abstract/Free Full Text]
|
| 22.
|
Kozyraki, R.,
Fyfe, J.,
Verroust, P. J.,
Jacobsen, C.,
Dautry-Varsat, A.,
Gburek, J.,
Willnow, T. E.,
Christensen, I. E.,
and Moestrup, S. K.
(2001)
Proc. Nat. Acad. Sci. U. S. A.
98,
12491-12496[Abstract/Free Full Text]
|
| 23.
|
Kozyraki, R.,
Fyfe, J.,
Kristiansen, M.,
Gerdes, C.,
Jacobsen, C.,
Cui, S.,
Christensen, E. I.,
Aminoff, M., De La,
Chapelle, A.,
Krahe, R.,
Verroust, P. J.,
and Moestrup, S. K.
(1999)
Nat. Med.
5,
656-661[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Sahali, D,
Mulliez, N,
Chatelet, F,
Laurent-Winter, C,
Citadelle, D,
Roux, C,
Ronco, P,
and Verroust, P.
(1992)
Am J. Pathol.
140,
33-44[Abstract]
|
| 25.
|
Le Panse, S.,
Ayani, E.,
Mulliez, N.,
Chatelet, F.,
Cywiner-Golenzer, C.,
Galceran, M.,
Citadelle, D.,
Roux, C.,
Ronco, P.,
and Verroust, P.
(1994)
Am. J. Pathol.
145,
1526-1536[Abstract]
|
| 26.
|
Seetharam, B.,
Christensen, E. I.,
Moestrup, S. K.,
Hammond, T. G.,
and Verroust, P.
(1997)
J. Clin. Invest.
99,
2317-2322[Medline]
[Order article via Infotrieve]
|
| 27.
|
Brent, R. I.,
Beckman, D. A.,
Jensen, M.,
and Koszalka, T. R.
(1990)
Teratology
41,
405-413[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Jollie, W. P.
(1990)
Teratology
41,
361-381[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Lloyd, J. B.
(1990)
Teratology
41,
383-393[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Croy, B. A.,
Luross, J. A.,
Guimond, M-J.,
and Hunt, J. S.
(1996)
Nat. Immunol.
15,
22-33
|
| 31.
|
Head, J. R.
(1996)
Nat. Immunol.
15,
7-21
|
| 32.
|
Parr, E. L.,
Young, L. H. Y.,
Parr, M. B.,
and Young, J. D-E.
(1990)
J. Immunol.
145,
2365-2372[Abstract]
|
| 33.
|
Gambel, P.,
Croy, B. A.,
Moore, W. D.,
Hunziker, R. D.,
Wegmann, T. G.,
and Rossant, J.
(1985)
Cell. Immunol.
93,
303-314[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Croy, B. A.,
Reed, N.,
Malashenko, B-A.,
Kim, K.,
and Kwon, B. S.
(1991)
Cell. Immunol.
133,
116-126[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Croy, B. A.,
Guilbert, L. J.,
Browne, M. A.,
Gough, N. M.,
Stinchcomb, D. T.,
Reed, N.,
and Wegmann, T. G.
(1991)
J. Reprod. Immunol.
19,
149-166[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Kusakabe, K.,
Ohmoto, M.,
Okada, T.,
Mukamoto, M.,
Sasaki, F.,
and Kiso, Y.
(1999)
J. Vet. Med. Sci.
61,
947-949[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Burkhardt, J. K.,
Hester, S.,
Lapham, C. K.,
and Argon, A.
(1990)
J. Cell Biol.
111,
2327-2340[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Q. He, M. Madsen, A. Kilkenney, B. Gregory, E. I. Christensen, H. Vorum, P. Hojrup, A. A. Schaffer, E. F. Kirkness, S. M. Tanner, et al.
Amnionless function is required for cubilin brush-border expression and intrinsic factor-cobalamin (vitamin B12) absorption in vivo
Blood,
August 15, 2005;
106(4):
1447 - 1453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. von Wolff, X. Wang, H.-J. Gabius, and T. Strowitzki
Galectin fingerprinting in human endometrium and decidua during the menstrual cycle and in early gestation
Mol. Hum. Reprod.,
March 1, 2005;
11(3):
189 - 194.
[Abstract]
[Full Text]
[PDF]
|
 |
|